Menu
Close

Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster

lse:fum

#121

I have to agree regarding the volatility of FUM shares: I’m quite convinced it’s down to day traders!

If you read the posts especially in the other main LSE board, it is littered with messages from day traders. For these guys a month in a stock is like a few years to long term holders. They pile in on high volume when there is expectation of a potential stock moving event. Just as quickly as they went in, they leave again causing huge volatility (& nervousness) for the long term holders to bear.

They like the fact that FUM has the propensity to ‘multi bag’ but they don’t have the patience or inclination to invest for the long term. So instead they ride the ‘up waves’ making them very sharp. And of course, when they sell to book their profits, you get the sharp down turn.

These guys use their ‘charting’ to help time these entry & exit points.

Day traders have their favourite stock lists that give a good propensity for volatility. Unfortunately, due to the quite illiquid nature of FUM stock, it makes it a perfect contender.

For us long term holders, we just need to sit tight and try to ignore this extreme volatility.

As I’ve mentioned before, the future of FUM lies in the chemistry of their products. I believe in this the team are very strong. They are inexperienced from a business savvy perspective, but I think they’re learning from their past mistakes.

Ultimately, success or failure will come down to the chemistry.

GLA & keep the faith!


#122

Well said fx!


#123

Prior to the release of the first part of Phase 3 results, and assuming FUM continues down a positive pathway, rather than a gentle slope upwards in stock price, the Day Traders are causing a highly jagged pattern (thanks to rapid entry & exit en masse).

I would guess that as soon as the Day Trading herd sense a near term bottom is reached, they’ll pile back in for more of the same. Unfortunately, this will be ongoing probably until the first Phase 3 results are out.

As the risk of failure of Phase 3 trials of MED diminishes, the probability for takeover increases. I am quite confident that, assuming successful data from the first phase 3 results, a bidding war will probably result, and possibly even before hand.

The ED market is a very large one. I believe that the differentiation of MED makes it a potential game-changing product. If you had problems with ED, which product would you choose?..one that you can use as part of the foreplay or a pill that you need to time just right (an hour in advance ensuring you haven’t eaten or drunk too much)?

There’ll be a big appetite for this from a few of the big boys. Then add to this the fact that if FUM as an entirety is purchased, If you own the market dominating condom product (RB), would you risk a major competitor getting hold of CSD500?

Death or The Promised Land all hinges on the data from part I of the Phase 3 trials. If it’s great data, I cannot imagine any Pharma would want a licensing deal. They’ll want full rights (& full profits). Plus the DermaSys delivery method could have several other uses (other than the pain portfolio).

The stock is at a crazy low price for all you get with FUM. So hang in tight and try not to get too nervous with the daily volatility!


#124

starting to buy back my shares which i sold in the 20p area ,it was clear that stock would pullback after such a massive rally . Next major milestone will be the approval of tpr100 likely to happen next quarter and maybe we get some partnership news before the approval however stock is a pure gift at this price .

Erectile dysfunction: giving patients more choice and better treatments

Futura Medical is optimistic about the outcome of this trial; it expects results to be published at the end of 2019 and for regulatory filings to follow in the second half of 2020.


#125

its in green again back to 20p quickly stock is oversold


#126

good news likely on the wayy and if buyout then stock will explode …fum is super attractive here at ridiculous valuation of 26 million


#127

uuuuuup she goes ,still think that takeover or partnership will happen before phase 3 readout …phase 3 ongoing for around 5 months now maybe those who are interested in med like what they see


#128

Market cap 27 million /Cash 10.5 million / Potency Drug with 2 BILLION Market potential /CSD500 Condom approved in Europe and many Countries outside of Europa + more Approvals & Licensing deals coming / TPR100 (Topical Gel for Pain ) first approval expected next Quarter = POTENTIAL 10++ BAGGER GEM RALLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY

Market potential

The market for ED undoubtedly offers Futura a huge opportunity. Independent market research conducted on the company™s behalf indicates MED2005 could generate potentially $1bn (£781m) in annual sales from both prescription and over-the-counter sales priced at $5 (£3.90) per dose. The prescription market alone was worth over $5.6bn in 2016. The profit margin on the product, which will have patent protection, is massive, too, as the cost is expected to be under ‚¬0.30 per dose (26.5p). Extensive work is being carried out to produce the chemistry, manufacturing and controls package required for regulatory submission and to establish the supply chain. A huge addressable market and profit margin makes this a blue-sky opportunity.


#129

and uuuuuup she goes again…there is no resistance untill around 25p


#130

Are you bioking on ADVFN?


#131

yes have an account there


#132

Notice of Preliminary Results

05 March 2019

Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, will announce its preliminary results for the year ended 31 December 2018 on Wednesday 10 April 2019.
James Barder, Chief Executive Officer, and Angela Hildreth, Finance Director/Chief Operating Officer, will host a presentation for analysts at 10am BST on the day of the results at the office of N+1 Singer at 1 Bartholomew Lane, London EC2N 2AX.
A copy of the announcement will be made available on the Futura Medical website and following the results meeting a webcast of the presentation to analysts will also be made available within the Investor Centre section of the site.

For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Broker:
N+1 Singer
Aubrey Powell/ Ben Farrow (Corporate Finance)
Mia Gardner / Tom Salvesen (Corporate Broking)
Tel: +44 (0) 20 7496 3000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144

Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com


#133

And do you repeatedly post the same long winded cut and post comments on there?


#134

Yes & yes is the answer to that lol.

Although i hold 147,641 shares at 14.9p, Hoping this drops back as i have a 15k order at 12.8p. Long term before results 27p easily


#135

When does the rally start? The Mcap is low. News are comming. We wait for the 10. April for Preresults. TPR100 (Topical Gel for Pain ) first approval expected next Quarter.
Everything is manageable. Nevertheless the stock Price is at 15p. it must be at 40p.


#136

I wouldn’t expect anything to come on results apart from a repeat of any positives they did in the last 6 months + updated cash burn.
TRP end of Q2, probably nothing until then.


#137

Futura Medical – Exciting milestone approaches… By Mark Watson-Mitchell 14 March 2019
https://masterinvestor.co.uk/equities/futura-medical-exciting-milestone-approaches/


#138

What happens next? in 20 days coming the news !


#139

looks like good news are coming :):):slight_smile:


#140

Nice to be back in the “blue”